Spikevax 50 micrograms dispersion for injection in pre-filled syringe COVID-19 mRNA Vaccine

DRUG2 trials

Sponsors

Finnish Institute For Health And Welfare, Gentofte Hospital, Moderna Inc.

Conditions

COVID-19 infectionSARS-CoV-2 infection

Phase 4

COVID-19 vaccine immunological studies in Finland

CompletedCTIS2024-517357-27-00

Finnish Institute For Health And WelfareCOVID-19 infection

Start: 2021-12-07End: 2025-12-17Target: 4000Updated: 2025-02-05

A Phase 4 Pragmatic, Randomized Trial to Evaluate the Effectiveness and Safety of mRNA-1273 Variant-Containing Vaccine Formulation Against Severe Outcomes in Adults Aged 50-64 Years Without Risk Factors for Severe COVID-19 (DAN-COVID)

RecruitingCTIS2025-523841-82-00

Gentofte Hospital, Moderna Inc.SARS-CoV-2 infection

Start: 2025-12-11Target: 275000Updated: 2025-11-26